A phase II clinical trial evaluating a personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma, demonstrated a 42% reduction in risk of disease progression or death at 6.9 months.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
